Page 327 - ATP-P 11th Ed
P. 327

Indications:
        •  Prevention of mild to moderate malaria caused by Plasmodium falciparum (including
          chloroquine-resistant strains) and P. vivax
        •  Treatment of mild to moderate malaria caused by mefloquine-susceptible strains of
          P. falciparum (both chloroquine-susceptible and resistant strains) and P. vivax
        Adult dose:
        •  Prophylaxis: 250mg once weekly
          °   Initiate therapy 1 to 2 weeks prior to departure to endemic area.
          °   Dose must be administered on same day of week.
          °   Continue prophylaxis for 4 additional weeks upon return from endemic area.
        •  Treatment: 5 tablets (1250mg) to be given as a split dose taken 6–8hr apart.
        •  Do not take on empty stomach.
        •  Take with at least 240mL (8oz) glass water.
        Pediatric dose:
        •  Prophylaxis:
          °    Children >45kg: one 250mg tablet should be taken in children
          °    Children <45kg: weekly dose decreases in proportion to body weight (3 to 5mg/kg   SECTION 3
            once weekly):
            •  30–45kg: ¾ tablet
            •  >20–30kg: ½ tablet
            •  Up to 20kg: ¼ tablet
            •  Experience with mefloquine in infants <3 months or weighing <5mg is limited
          °   Initiate therapy 1 week prior to departure to endemic area.
          °   Dose must be administered on same day of week.
          °   Continue prophylaxis for 4 additional weeks upon return from endemic area.
        •  Treatment: 20–25mg/kg for nonimmune patients
          °   Splitting the dose into 2 doses taken 6–8 hours apart may reduce adverse effects.
          °    Treatment in children has been associated with early vomiting; if patient vomits within
            30min of dose and a significant loss of drug is suspected by inspection of emesis, re-
            dose patient with full dose; if vomiting occurs within 30 to 60 minutes, administer ½
            the full dose.
          °    Do not administer on an empty stomach and give with ample water.
          °    For very young patients, dose may be crushed, mixed with water or sugar water and
            may be administered via oral syringe.
          °   Experience in infants <3 months or <5kg is limited.
        Contraindications:
        •  Hypersensitivity to related compounds (e.g., quinine, quinidine)
        •  Patients with:
          °   Active depression
          °   Recent history of depression

                                              ATP-P Handbook 11th Edition 317
   322   323   324   325   326   327   328   329   330   331   332